Vanberra Signal
Free trial

Docphin

Curated by Signal

Research Libraries for Physicians

Health Technologydocphin.com

Overview

Docphin is a free platform that personalizes medical news and research instantly. Docphin helps physicians organize, bookmark, read and track medical news and research from a variety of sources, all within a single dashboard interface. The resulting product has a very consumer-like feel, especially with features like a Twitter widget for tracking medical societies’ tweets, bookmarking, commenting and social sharing.It has also moved to an HTML5 platform and has added features like a “Trending” section that shows what others are reading, sharing and discussing as well as a new “Search” page that lets doctors filter content from Docphin’s news sources and journals and more.

Key facts

Founded
2010
Headquarters
New York City, United States
Stage
Sign up to view
Industry
Health Technology

More on Vanberra Signal

Members only
Business overviewCore metrics and financialsPeopleLeadership and key peopleSimilar companiesPeers and competitorsDeep AnalysisAI-generated strategic report

Competitors & similar companies

More Health Technology companies

  • Gardeen

    Provider of wearable device for elders to detect movements

    Health TechnologyNorwell, United States

  • MediYeti

    Provider of EHR software for healthcare professionals

    Health TechnologySalt Lake City, United States

  • Empowered Fitness Training

    Provider of an online fitness training & schedule management platform

    Health TechnologyEllensburg, United States

About Docphin

What does Docphin do?

Docphin is a free platform that personalizes medical news and research instantly.

Where is Docphin headquartered?

Docphin is headquartered in New York City, United States.

When was Docphin founded?

Docphin was founded in 2010.

Which sector is Docphin in?

Docphin operates in Health Technology.

Who are Docphin's competitors?

Companies similar to Docphin include Gardeen, MediYeti, and Empowered Fitness Training.